Incyte News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

09.08.13	Pharmaceutical Companies Announce Quarterly Financial Results - Research Report on Jazz, Acadia, Arena, Santarus, and Incyte (PR Newswire)
02.08.13	ATRC, RGEN See Rosy Future, VICL, INCY To Watch Out For, PCRX Down But Not Out (RTTNews)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
29.07.13	Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope (PR Newswire)
25.07.13	Results Schedules, Management Changes, and Pending NDA Approvals - Research Report on Questcor, VIVUS, Exelixis, Incyte, and Chelsea Therapeutics (PR Newswire)
20.04.12	Novartis: Blutkrebs-Mittel Jakavi von EU-Ausschuss zur Zulassung empfohlen (AF) (AWP)
05.01.10	Incyte to Present at the 28th Annual JPMorgan Healthcare Conference (Businesswire)
05.11.09	Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs (Businesswire)
24.09.09	Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock (Businesswire)
21.04.09	Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7 (Businesswire)
06.12.08	Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients (Businesswire)
06.11.08	Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results (Businesswire)
11.06.08	Incyte to Host EULAR Webcast and Conference Call on June 12 (Businesswire)
14.02.08	Incyte Reports Progress in Multiple Clinical Programs; Expands JAK Inhibitor Program; Announces 2007 Financial Results and Provides 2008 Financial Guidance (Businesswire)
24.07.07	Phase IIa Study Results Demonstrate that Once-Daily 200 mg Dosing of INCB9471 Provided Potent and Prolonged Antiviral Activity in HIV-Infected Patients (Businesswire)
04.05.05	Incyte Announces First Quarter 2005 Results; Progress Achieved in Top (Businesswire)
24.03.05	Incyte to Present at Lehman and BioCentury Conferences (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	81.18	4.37 %	K V
Part Grp Hldg	1’299.00	3.05 %	K V
Lonza Grp	556.20	2.66 %	K V
Roche Hldg G	262.40	1.90 %	K V
Sonova Hldg	299.10	1.63 %	K V
Zurich Insur Gr	549.00	0.18 %	K V
Holcim	88.52	0.05 %	K V
ABB	49.48	-0.26 %	K V
Sika	216.80	-0.41 %	K V
Kuehne+Nagel Int	208.20	-0.57 %	K V

mehr

04.12.24		Gewinne in New York: S&P 500 legt mittags zu
19.11.24		Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind
19.11.24		Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen
19.11.24		Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen
19.11.24		Verluste in New York: S&P 500 startet im Minus
29.10.24		Börse New York in Grün: S&P 500 beendet die Sitzung im Plus
29.10.24		Börse New York: S&P 500 fester
29.10.24		Optimismus in New York: So bewegt sich der S&P 500 am Mittag